Compare Stocks: TBPH, ARQT, TARS, and RGC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$26.19 -0.7%	$25.83	$16.57 ▼ $31.77	$3.32B	1.5	1.75 million shs	8,859 shs
RGC Regencell Bioscience	$5.98 +0.0%	$5.72	$4.51 ▼ $69.00	$3.02B	1.45	289,448 shs	1,962 shs
TARS Tarsus Pharmaceuticals	$75.24 +1.3%	$70.54	$53.89 ▼ $91.53	$3.29B	0.54	741,014 shs	732 shs
TBPH Theravance Biopharma	$17.05 +0.1%	$16.97	$13.08 ▼ $21.03	$884.98M	0.25	680,323 shs	10.02 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	-5.04%	+0.92%	+6.46%	-1.16%	+49.89%
RGC Regencell Bioscience	-4.01%	+5.28%	+13.04%	-20.16%	-59.46%
TARS Tarsus Pharmaceuticals	-3.62%	-4.31%	+2.03%	+15.46%	+33.54%
TBPH Theravance Biopharma	0.00%	0.00%	+0.12%	-2.07%	+21.04%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$26.19 -0.7%	$25.83	$16.57 ▼ $31.77	$3.32B	1.5	1.75 million shs	8,859 shs
RGC Regencell Bioscience	$5.98 +0.0%	$5.72	$4.51 ▼ $69.00	$3.02B	1.45	289,448 shs	1,962 shs
TARS Tarsus Pharmaceuticals	$75.24 +1.3%	$70.54	$53.89 ▼ $91.53	$3.29B	0.54	741,014 shs	732 shs
TBPH Theravance Biopharma	$17.05 +0.1%	$16.97	$13.08 ▼ $21.03	$884.98M	0.25	680,323 shs	10.02 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	-5.04%	+0.92%	+6.46%	-1.16%	+49.89%
RGC Regencell Bioscience	-4.01%	+5.28%	+13.04%	-20.16%	-59.46%
TARS Tarsus Pharmaceuticals	-3.62%	-4.31%	+2.03%	+15.46%	+33.54%
TBPH Theravance Biopharma	0.00%	0.00%	+0.12%	-2.07%	+21.04%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.67	Moderate Buy	$35.57	35.84% Upside
RGC Regencell Bioscience	1.00	Sell	N/A	N/A
TARS Tarsus Pharmaceuticals	2.70	Moderate Buy	$100.86	34.05% Upside
TBPH Theravance Biopharma	2.00	Hold	$19.40	13.82% Upside

Current Analyst Ratings Breakdown

Latest TBPH, ARQT, TARS, and RGC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	TARS Tarsus Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$116.00
9/24/2026	TBPH Theravance Biopharma	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/21/2026	RGC Regencell Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/16/2026	TARS Tarsus Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$110.00
9/16/2026	TARS Tarsus Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$110.00
9/8/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
9/8/2026	TARS Tarsus Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$88.00 ➝ $105.00
9/7/2026	TBPH Theravance Biopharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/4/2026	TARS Tarsus Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$88.00 ➝ $105.00
8/20/2026	ARQT Arcutis Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/17/2026	TBPH Theravance Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$463.98M	7.09	N/A	N/A	$1.55 per share	16.89
RGC Regencell Bioscience	N/A	N/A	N/A	N/A	$0.01 per share	N/A
TARS Tarsus Pharmaceuticals	$606.33M	5.45	N/A	N/A	$8.09 per share	9.30
TBPH Theravance Biopharma	$107.46M	8.24	N/A	N/A	$5.86 per share	2.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$16.14M	$0.21	125.64	22.97	N/A	6.15%	15.05%	6.51%	10/27/2026 (Estimated)
RGC Regencell Bioscience	-$3.58M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	-$66.42M	-$1.09	N/A	132.00	N/A	-7.67%	-13.53%	-8.12%	11/3/2026 (Estimated)
TBPH Theravance Biopharma	$105.89M	$1.01	16.88	21.04	N/A	51.58%	-0.77%	-0.46%	11/10/2026 (Estimated)

Latest TBPH, ARQT, TARS, and RGC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	TBPH Theravance Biopharma	$0.0725	-$0.11	-$0.1825	-$0.11	$22.49 million	$20.73 million
8/6/2026	Q2 2026	TARS Tarsus Pharmaceuticals	-$0.1918	-$0.43	-$0.2382	-$0.43	$169.65 million	$173.91 million
8/5/2026	Q2 2026	ARQT Arcutis Biotherapeutics	$0.0551	$0.11	+$0.0549	$0.11	$118.85 million	$129.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
RGC Regencell Bioscience	$0.88	14.71%	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.46	2.92	2.67
RGC Regencell Bioscience	N/A	1.41	N/A
TARS Tarsus Pharmaceuticals	0.21	3.20	3.17
TBPH Theravance Biopharma	N/A	13.54	13.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
RGC Regencell Bioscience	0.13%
TARS Tarsus Pharmaceuticals	90.01%
TBPH Theravance Biopharma	99.10%

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
RGC Regencell Bioscience	2.00%
TARS Tarsus Pharmaceuticals	9.64%
TBPH Theravance Biopharma	7.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	354	125.69 million	113.88 million	Optionable
RGC Regencell Bioscience	10	494.49 million	484.60 million	N/A
TARS Tarsus Pharmaceuticals	50	43.88 million	39.65 million	Optionable
TBPH Theravance Biopharma	90	51.92 million	47.95 million	Optionable

TBPH, ARQT, TARS, and RGC Headlines

Recent News About These Companies

Theravance Biopharma (NASDAQ:TBPH) Receives Neutral Rating from BTIG Research

1 hour ago | marketbeat.com

Zymeworks Inc. (NasdaqGS:ZYME) hat Theravance Biopharma, Inc. (NasdaqGM:TBPH) übernommen.

3 hours ago | de.marketscreener.comD

Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P TMI Index

September 23 at 6:30 PM | marketscreener.comM

Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from S&P Global BMI Index

September 22 at 12:20 AM | marketscreener.comM

Theravance Biopharma (NASDAQ:TBPH) Sees Unusually-High Trading Volume - Still a Buy?

September 22 at 10:59 AM | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Rating of "Hold" by Analysts

September 22 at 4:15 AM | americanbankingnews.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Recommendation of "Hold" by Analysts

September 22 at 4:13 AM | marketbeat.com

Financial Analysis: Theravance Biopharma (NASDAQ:TBPH) & Urogen Pharma (NASDAQ:URGN)

September 21 at 8:00 AM | americanbankingnews.com

Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow

September 18, 2026 | seekingalpha.com

Theravance Biopharma (NASDAQ:TBPH) SVP Sells 13,314 Shares

September 18, 2026 | insidertrades.com

Insider Selling: Theravance Biopharma (NASDAQ:TBPH) SVP Sells 13,314 Shares

September 17, 2026 | marketbeat.com

VIRGINIA RETIREMENT SYSTEMS ET Al Invests $1.07 Million in Theravance Biopharma, Inc. $TBPH

September 14, 2026 | marketbeat.com

Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?

September 9, 2026 | zacks.com

Theravance Biopharma (NASDAQ:TBPH) Downgraded by Zacks Research to "Hold"

September 9, 2026 | marketbeat.com

Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?

September 9, 2026 | marketbeat.com

Theravance Biopharma, Inc. $TBPH is Newtyn Management LLC's 2nd Largest Position

August 31, 2026 | marketbeat.com

Bank of America Corp DE Raises Position in Theravance Biopharma, Inc. $TBPH

August 31, 2026 | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Short Interest Update

August 28, 2026 | marketbeat.com

Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Hold" by Analysts

August 28, 2026 | marketbeat.com

Theravance Biopharma Inc

August 20, 2026 | money.usnews.com

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

August 15, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TBPH, ARQT, TARS, and RGC Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$26.19 -0.19 (-0.74%)

As of 09:36 AM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Regencell Bioscience NASDAQ:RGC

$5.98 +0.00 (+0.02%)

As of 09:35 AM Eastern

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Tarsus Pharmaceuticals NASDAQ:TARS

$75.24 +0.95 (+1.28%)

As of 09:36 AM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Theravance Biopharma NASDAQ:TBPH

$17.05 +0.02 (+0.09%)

Closing price 09/23/2026 07:30 PM Eastern

Extended Trading

$17.05 0.00 (0.00%)

As of 09/23/2026 07:30 PM Eastern

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TBPH, ARQT, TARS, and RGC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TBPH, ARQT, TARS, and RGC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TBPH, ARQT, TARS, and RGC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TBPH, ARQT, TARS, and RGC Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

Regencell Bioscience NASDAQ:RGC

Tarsus Pharmaceuticals NASDAQ:TARS

Theravance Biopharma NASDAQ:TBPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TBPH, ARQT, TARS, and RGC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TBPH, ARQT, TARS, and RGC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TBPH, ARQT, TARS, and RGC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TBPH, ARQT, TARS, and RGC Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

Regencell Bioscience NASDAQ:RGC

Tarsus Pharmaceuticals NASDAQ:TARS

Theravance Biopharma NASDAQ:TBPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools